European sub-registry of chronic myelogenous leukemia (CML) patients (pts) in failure after imatinib therapy (IFP): Rationale, study design and current enrollment.

被引：0
|
作者：
Guilhot, Joelle
Tartarin, Florence
Pfirmann, Markus
Nagler, Arnon
Nicolini, Franck
Rousselot, Philippe
Porkka, Kimmo
Ossenkoppele, Gert
Stentoft, Jesper
Cervantes, Francisco
Rosti, Gianantonio
Thaler, Josef
le Coutre, Philipp
Hasford, Joerg
Hehlmann, Rudiger
Guilhot, Francois
机构：
[1] CHU La Miletrie, Clin Res Ctr, Poitiers, France
[2] Univ Innsbruck, A-6020 Innsbruck, Austria
[3] Charite Univ Med Berlin, Berlin, Germany
[4] Univ Heidelberg, D-6800 Mannheim, Germany
来源：
BLOOD | 2006年 / 108卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4764
引用
收藏
页码：274B / 274B
页数：1
相关论文
共 50 条
  • [31] EUROPEAN TREATMENT AND OUTCOME STUDY (EUTOS) SCORE PREDICTS EARLY MOLECULAR RESPONSE TO IMATINIB THERAPY IN CHRONIC PHASE CHRONIC MYELOID LEUKEMIA PATIENTS (CP-CML)
    Reddy, K. Sudheer
    Manickavasagam, M.
    Sampath, V. Venkata
    Barghavi, D.
    Vindhyavasini, A.
    Pai, A.
    Balambika, R. G.
    ANNALS OF ONCOLOGY, 2014, 25
  • [32] Cytopenias in patients (pts) with chronic myelogenous leukemia (CML) in chronic phase (CP) treated with dasatinib (SPRYCEL®):: Clinical features and management, including outcome after hematopoietic growth factor therapy.
    Quintas-Cardama, Alfonso
    Kantarjian, Hagop M.
    Nicaise, Claude
    Garcia-Manero, Guillermo
    O'Brien, Susan
    Ravandi, Farhad
    Faderl, Stefan
    BLOOD, 2006, 108 (11) : 613A - 614A
  • [33] Bosutinib As Third-Line Therapy in Patients (Pts) with Chronic Phase Chronic Myeloid Leukemia (CP CML) Following Failure with Imatinib Plus Dasatinib and/or Nilotinib: 48-Month Update of a Phase 1/2 Study
    Gambacorti-Passerini, Carlo
    Khoury, H. Jean
    Kantarjian, Hagop M.
    Lipton, Jeffrey H.
    Kim, Dong-Wook
    Schafhausen, Philippe
    Matczak, Ewa M.
    Leip, Eric
    Noonan, Kay
    Bruemmendorf, Tim H.
    Cortes, Jorge E.
    BLOOD, 2014, 124 (21)
  • [34] Survival outcomes for patients (Pts) with chronic myeloid leukemia (CML) with clonal evolution (CE) treated with 2nd generation tyrosine kinase inhibitors (TKI) after imatinib failure
    Verma, Dushyant
    Kantarjian, Hagop
    Estrov, Zeev
    Garcia-Mancro, Guillermo
    Koller, Charles
    Borthakur, Gautam
    Cortes, Jorge
    BLOOD, 2007, 110 (11) : 866A - 867A
  • [35] Efficacy of dasatinib (SPRYCEL®) in patients (pts) with chronic phase chronic myelogenous leukemia (CP-CML) resistant to or intolerant of imatinib:: Updated results of the CA180013 'START C' phase II study.
    Baccarani, Michele
    Kantarjian, H. M.
    Apperley, J. F.
    Lipton, J. H.
    Druker, B.
    Countouriotis, A.
    Ezzeddine, R.
    Hochhaus, A.
    BLOOD, 2006, 108 (11) : 53A - 53A
  • [36] A phase II study of AMN107, a novel inhibitor of Bcr-Abl, administered to imatinib-resistant or intolerant patients (pts) with chronic myelogenous leukemia (CML) in accelerated phase (AP).
    Le Coutre, P. D.
    Ottmann, O.
    Gatterman, N.
    Larson, R.
    Rafferty, T.
    Alland, L.
    Tavorath, R.
    Giles, F.
    O'Brien, S. G.
    Kantarjian, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 344S - 344S
  • [37] Dasatinib compared to imatinib (IM) in patients (pts) with newly diagnosed chronic-phase chronic myelogenous leukemia in chronic phase (CML-CP): Twelve-month efficacy and safety from the phase III DASISION study
    Kantarjian, H.
    Shah, N. P.
    Hochhaus, A.
    Cortes, J. E.
    Shah, S.
    Ayala, M.
    Moiraghi, B.
    Bradley-Garelik, M.
    Zhu, C.
    Baccarani, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (18)
  • [38] Nilotinib therapy after dasatinib failure in patients with imatinib-resistant or -intolerant chronic myeloid leukemia (CML) in chronic phase (CP), accelerated phase (AP) or blast crisis (BC)
    Giles, Francis J.
    le Coutre, Phillip
    Bhalla, Kapil N.
    Ossenkoppele, Gert
    Alimena, Giuliana
    Haque, Ariful
    Gallagher, Neil
    Kantarjian, Hagop M.
    BLOOD, 2007, 110 (11) : 311A - 312A
  • [39] Outcomes of Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Patients (pts) After Surviving 5 Years of Initial Therapy with Interferon Alpha (IFN), Imatinib (IMA) or Allogeneic Stem Cell Transplantation (ASCT)
    Ghanem, Hady
    Kantarjian, Hagop M.
    Champlin, Richard E.
    Katragadda, Lakshmikanth
    Rondon, Gabriela
    Jabbour, Elias J.
    Quintas-Cardama, Alfonso
    Pierce, Sherry A.
    Cortes, Jorge E.
    BLOOD, 2012, 120 (21)
  • [40] Sustained Superior Long-Term Outcomes of Imatinib Therapy In Japanese Patients with Newly Diagnosed Chronic Myelogenous Leukemia In Chronic Phase: Sub-Analysis According to the Mean Daily Dose of Imatinib and the Plasma Trough Levels In JALSG CML202 Study After 66 Months Follow-up
    Nakaseko, Chiaki
    Ohnishi, Kazunori
    Takeuchi, Jin
    Fujisawa, Shin
    Nagai, Tadashi
    Ohtake, Shigeki
    Yamazaki, Hirohito
    Tauchi, Tetsuzo
    Imai, Kiyotoshi
    Mori, Naoki
    Yagasaki, Fumiharu
    Akiyama, Hideki
    Maeda, Yasuhiro
    Usui, Noriko
    Saburi, Yoshio
    Ishida, Takashi
    Kosugi, Hiroshi
    Miyamura, Koichi
    Miyazaki, Yasushi
    Handa, Hiroshi
    Yokota, Akira
    Matsumoto, Kenji
    Fujimaki, Katsumichi
    Matsui, Toshimitsu
    Kiyoi, Hitoshi
    Miyawaki, Shuichi
    Ohno, Ryuzo
    Naoe, Tomoki
    BLOOD, 2010, 116 (21) : 1400 - 1400
12345